Lung cancer

Novel therapies begin to ‘outsmart’ ALK-positive NSCLC

Rare ALK+ non-small cell lung cancer (NSCLC) can achieve an ‘impressive’ overall survival of almost four years (46 months) when aggressively managed, Australian clinicians have shown. A study of 35 patients identified between 2010 and 2016 at the Royal North Shore Hospital found most patients (54%) were managed on a single line of therapy, typically ...

Already a member?

Login to keep reading.

© 2021 the limbic